Skip to main content
See every side of every news story
Published • loading... • Updated

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Summary by BizToc
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched…

4 Articles

Lean Right

A new Chinese anticancer drug, which was expected to surpass Keytruda—the world's best-selling anticancer drug manufactured by Merck (MSD)—failed to clear the approval threshold of the U.S. Food and Drug Administration (FDA). Although the drug garnered attention for demonstrating superior therapeutic efficacy compared to Keytruda in clinical trials involving Chinese patients, analysts suggest that the lack of sufficient data from patients in Wes…

Akeso's actions fell to 31.8% after Summit Therapeutics reported that the FDA did not consider that ivonescimab had demonstrated substantial evidence of efficacy.The setback occurred despite the attention the drug aroused after beating Keytruda in an advanced trial in China.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

South China Morning Post broke the news in Hong Kong, Hong Kong on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal